Improved final height with long-term growth hormone treatment in Noonan syndrome.

Osio D, Dahlgren J, Wikland KA, Westphal O

Acta paediatrica (Oslo, Norway : 1992)1 Sept 2005Cited by 57 (Europe PMC)

PMID16203673DOI10.1111/j.1651-2227.2005.tb02081.xPepBankPUB-16203673

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
In children with Noonan syndrome, growth hormone treatment increased final height by 1.7 SDS, equivalent to 10.4 cm from pretreatment height.
In plain wordsIn children with Noonan syndrome, final height increased by 10.4 cm relative to pretreatment height.
Peptide
HGH (somatotropin)
Outcome
IncreaseFinal height gain
Study
n = 18
Comparator
Pre-treatment height
Outcome group
Linear growth · Musculoskeletal
Studied dose
33 or 66 microg/kg/d · at least 2 yAs given in this study (human).
Measurements
Improvement in final height
1.7 SDS
compared to pre-treatment height; 18 patients reached final height
Improvement in final height
10.4 cm
compared to pre-treatment height; 18 patients reached final height
Source sentences
Summary
A substantial improvement in FH of 1.7 SDS, equivalent to 10.4 cm compared to pre-treatment height, was observed.
3 context sentences(design, population, supporting numbers)
Summary · context
Eighteen out of 25 patients reached FH.
Summary · context
Twenty-five prepubertal children (13 girls) with Noonan syndrome (NS) were studied.
Summary · context
GH treatment started at an age ranging from 3.1 to 13.8 y and was continued for at least 2 y.
Report a problemFND-1620367301
02HumanObservational studyEfficacy outcome
In children with Noonan syndrome, final height gain did not differ significantly between the two growth hormone doses.
In plain wordsIn children with Noonan syndrome, height gain did not differ significantly between the two growth hormone doses.
Peptide
HGH (somatotropin)
Outcome
No significant changeFinal height dose comparison
Study
n: not reported in source
Comparator
33 versus 66 microg/kg/d
Outcome group
Linear growth · Musculoskeletal
Studied dose
33 or 66 microg/kg/d · at least 2 yAs given in this study (human).
Source sentences
Summary
No significant difference was seen between the two GH doses.
3 context sentences(design, population, supporting numbers)
Summary · context
Ten children received a GH dose of 33 microg/kg/d (mean age at start 7.7+/-2.1 y, mean age at stop 17.6+/-1.7 y) and 15 received a dose of 66 microg/kg/d (mean age at start 8.6+/-3.3 y, mean age at stop 18.4+/-2.1 y).
Summary · context
Twenty-five prepubertal children (13 girls) with Noonan syndrome (NS) were studied.
Summary · context
GH treatment started at an age ranging from 3.1 to 13.8 y and was continued for at least 2 y.
Report a problemFND-1620367302
03HumanObservational studyEfficacy outcome
In females with Noonan syndrome given growth hormone, mean height gain at final height was 9.8 cm.
In plain wordsIn females with Noonan syndrome given growth hormone, mean height gain at final height was 9.8 cm.
Peptide
HGH (somatotropin)
Outcome
IncreaseFemale final height gain
Study
n: not reported in source
Outcome group
Linear growth · Musculoskeletal
Studied dose
33 or 66 microg/kg/d · at least 2 yAs given in this study (human).
Measurements
Mean height gain at final height
9.8 cm
females
Source sentences
Summary
Females gained a mean height of 9.8 cm and males 1-13 cm (FH 174.5+/-7.8 cm vs mean adult height of 162.5+/-5.4 cm for males with NS) at final height.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-five prepubertal children (13 girls) with Noonan syndrome (NS) were studied.
Summary · context
GH treatment started at an age ranging from 3.1 to 13.8 y and was continued for at least 2 y.
Report a problemFND-1620367303
04HumanObservational studyEfficacy outcome
In males with Noonan syndrome given growth hormone, reported height gain at final height was 1-13 cm.
In plain wordsIn males with Noonan syndrome given growth hormone, reported height gain at final height was 1-13 cm.
Peptide
HGH (somatotropin)
Outcome
IncreaseMale final height gain
Study
n: not reported in source
Outcome group
Linear growth · Musculoskeletal
Studied dose
33 or 66 microg/kg/d · at least 2 yAs given in this study (human).
Measurements
Height gain at final height
1 to 13 cm
males; reported as 1-13 cm
Source sentences
Summary
Females gained a mean height of 9.8 cm and males 1-13 cm (FH 174.5+/-7.8 cm vs mean adult height of 162.5+/-5.4 cm for males with NS) at final height.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-five prepubertal children (13 girls) with Noonan syndrome (NS) were studied.
Summary · context
GH treatment started at an age ranging from 3.1 to 13.8 y and was continued for at least 2 y.
Report a problemFND-1620367304
05HumanObservational studyEfficacy outcome
In males with Noonan syndrome given growth hormone, final height was 174.5+/-7.8 cm versus a reference mean adult height of 162.5+/-5.4 cm for males with Noonan syndrome.
In plain wordsIn males with Noonan syndrome, final height with growth hormone exceeded the reported male reference height.
Peptide
HGH (somatotropin)
Outcome
IncreaseMale final height
Study
n: not reported in source
Comparator
mean adult height for males with Noonan syndrome
Outcome group
Linear growth · Musculoskeletal
Studied dose
33 or 66 microg/kg/d · at least 2 yAs given in this study (human).
Measurements
Final height (mean, +/- 7.8)
174.5 cm
males with NS, GH-treated
Mean adult height (+/- 5.4)
162.5 cm
males with NS, reference value
Source sentences
Summary
Females gained a mean height of 9.8 cm and males 1-13 cm (FH 174.5+/-7.8 cm vs mean adult height of 162.5+/-5.4 cm for males with NS) at final height.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-five prepubertal children (13 girls) with Noonan syndrome (NS) were studied.
Summary · context
GH treatment started at an age ranging from 3.1 to 13.8 y and was continued for at least 2 y.
Report a problemFND-1620367305
06HumanObservational studyEfficacy outcome
In children with Noonan syndrome given growth hormone, 60% reached a mid-parental height of+/-1 SD.
In plain wordsIn children with Noonan syndrome given growth hormone, 60% reached within the reported range around mid-parental height.
Peptide
HGH (somatotropin)
Outcome
Not applicableMid-parental height attainment
Study
n: not reported in source
Outcome group
Linear growth · Musculoskeletal
Studied dose
33 or 66 microg/kg/d · at least 2 yAs given in this study (human).
Measurements
Patients reaching mid-parental height of +/-1 SD
60%
children with Noonan syndrome given GH
Source sentences
Summary
Moreover, 60% reached a mid-parental height of+/-1 SD.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-five prepubertal children (13 girls) with Noonan syndrome (NS) were studied.
Summary · context
GH treatment started at an age ranging from 3.1 to 13.8 y and was continued for at least 2 y.
Report a problemFND-1620367306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT01529840

Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome

Novo Nordisk A/Sn = 24Jun 1990 to Sept 2005

Genetic Disorder · Noonan Syndrome

Trial page ClinicalTrials.govUpdated 18 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.